| | The information set forth in or incorporated by reference in Items 3 and 6 of this Schedule 13D is hereby incorporated herein by reference.
This Amendment amends and supplements Item 4 of the Original Schedule 13D by adding the following:
Transaction Agreement
Consideration
Under the Transaction Agreement, each Class A ordinary share of the Issuer (the "Class A Ordinary Shares") not held by members of the Consortium or their respective Affiliates, not held in treasury by the Issuer and not a Rollover Share (each, a "Cash-Out Share") will be transferred to the Purchaser for $7.02 in cash, without interest and subject to applicable withholding taxes (the "Consideration"), as of the time at which the Court Sanction Order is delivered to the Registrar of Companies (the "Effective Time", and such date on which the Effective Time occurs, the "Effective Date").
Rather than receiving the Consideration, each shareholder of the Issuer (a "Shareholder") (other than any Shareholder residing in India, who may not elect to participate in the Rollover) may elect, by delivering an election notice (the "Rollover Election Notice") no later than the later of (i) 80 days following the publication of the circular sent by the Issuer to its shareholders and (ii) ten business days prior to the hearing of the High Court of Justice of England and Wales (the "Court") sanctioning the Scheme (the "Rollover Election Deadline"), to retain all of its shares of the Issuer, which will remain outstanding following the Scheme and in respect of which no Consideration or other distributions will be paid (a "Rollover", the shares so retained (and subject to the cutbacks described below), the "Rollover Shares", and any Shareholder holding any Rollover Shares, a "Rollover Shareholder"). Notwithstanding the foregoing, if the total number of Shareholders immediately following the consummation of the Scheme and after giving effect to the Rollover Election Notices validly delivered is expected to exceed 200, then any Shareholder holding fewer shares of the Issuer than the Cutback Threshold (as defined below) shall be deemed to have elected to treat all of its shares as Cash-Out Shares, and such Shareholder's shares shall not be treated as Rollover Shares. The "Cutback Threshold" will be set at such number of issued and outstanding shares of the Issuer as of the Rollover Election Deadline that, when giving effect to the Rollover, will cause the total number of Shareholders following consummation of the Scheme to not exceed 200. Additionally, if the number of Rollover Shareholders that are persons located in the United States or are otherwise United States residents (a "U.S. Rollover Shareholder") would be expected to represent more than 9% of the total issued and outstanding shares of the Issuer (the "Maximum U.S. Rollover Percentage") following the consummation of the Scheme, the number of Rollover Shares held by each U.S. Rollover Shareholder will be reduced on a pro rata basis to the minimum extent necessary such that the aggregate Rollover Shares of all U.S. Rollover Shareholders would not exceed the Maximum U.S. Rollover Percentage following the consummation of the Scheme. Any Rollover Shares reduced to comply with the Maximum U.S. Rollover Percentage will instead be treated as Cash-Out Shares.
Treatment of Equity Awards
Under the Issuer's 2021 Incentive Award Plan and Non-Employee 2021 Incentive Award Plan, outstanding options, restricted share units ("RSUs") and performance-based restricted share units ("PBUs") (other than Founder-held awards, collectively the "Awards") will be treated as follows, conditional on the Court's order sanctioning the Scheme (the "Court Sanction Order"):
(a) Awards (i) granted under the Issuer's Non-Employee 2021 Incentive Award Plan to independent directors of the Issuer ("ID Awards"), (ii) held by former employees (including persons who become former employees following the date of the Transaction Agreement) ("Former Employee Awards") or (iii) held by non-India residents ("Non-Resident Awards") will immediately vest and become exercisable upon the Court Sanction Order. Any such Award that remains unexercised as of the date and time specified in the circular of the Scheme (the "Scheme Record Time") will lapse, and the holder will instead receive cash equal to the product of (a) the number of Class A Ordinary Shares underlying such Award multiplied by (b) the Consideration minus the per share exercise price.
(b) Awards (other than ID Awards, Former Employee Awards and Non-Resident Awards) with an exercise price per share at or below the Consideration ("ITM Awards") and a six month or less vesting period remaining as of the Effective Date will immediately vest and become exercisable upon the Court Sanction Order ("Accelerated ITM Awards").
(c) ITM Awards already vested prior to the Court Sanction Order and Accelerated ITM Awards (together, "Exercisable ITM Awards") may be exercised before the Scheme Record Time; provided that, subject to holder consent, combined exercises of Exercisable ITM Awards and Non-Resident Awards may not exceed 60% of the net cash value of the Class A Ordinary Shares underlying the Non-Resident Awards and Exercisable ITM Awards after accounting for exercise prices and employee taxes, excluding former-employee holdings, based on outstanding Awards as of the date of the Transaction Agreement. If such exercises exceed the 60% cap, subject to holder consent, the number of employees' exercised Exercisable ITM Awards will be reduced pro rata by reference to each holder's total holding of Accelerated ITM Awards and the aggregate amount of Accelerated ITM Awards.
(d) Exercisable ITM Awards unexercised or unsettled as of the Scheme Record Time will lapse, and the holder will instead receive, within five business days of the Effective Date, replacement awards vesting on the 12-month anniversary of the Effective Date at a 0.8289 conversion ratio (as adjusted, the "Conversion Ratio") under a new incentive plan to be established by ReNew Private Limited, a wholly-owned subsidiary of the Issuer ("RPL") following the Effective Date.
(e) ITM Awards with 6 to 12 months of vesting remaining will lapse on the Effective Date, and (subject to holder consent) the holder will receive, within five business days of the Effective Date, replacement awards under the new incentive plan vesting on the 12-month anniversary of the Effective Date using the Conversion Ratio.
(f) If a holder is granted a replacement award under the new incentive plan that vests on the 12-month anniversary of the Effective Date, and his or her employment ends (other than for cause) within 12 months of the Effective Date, the holder may elect to keep such award or receive cash equal to the number of Class A Ordinary Shares that would have vested by the cessation date under the original schedule multiplied by the Consideration minus the per share exercise price.
(g) Options with an exercise price per share greater than the Consideration ("Underwater Options") will be replaced, within five business days of the Effective Date, with replacement awards under the new incentive plan using the Conversion Ratio, vesting 75%/12.5%/12.5% on the 12-, 18- and 24-month anniversaries of the Effective Date.
(h) All other Awards will be replaced, within five business days of the Effective Date, with replacement awards under the new incentive plan on substantially the same vesting terms as the original Award, using the Conversion Ratio.
(i) Replacement award exercise prices shall be set using the USD / INR exchange rate on the Effective Date, except the options granted on August 23, 2021 for prior group stock options, which retain their original INR price.
Shareholder Approval
The Transaction requires (i) the approval of a majority in number of the Shareholders present and voting and who represent at least 75% in value of the Class A Ordinary Shares voted by the Shareholders present and voting at a meeting of the Shareholders convened for the purpose of approving the Scheme (the "Court Meeting") and (ii) the passing of a resolution of the Shareholders to amend the articles of association of the Issuer and approve such other matters as may be necessary to facilitate the implementation of the Transaction and the Scheme (the "Company Shareholder Resolution") by Shareholders representing not less than 75% of the total voting rights of the Shareholders present and voting at a general meeting of the Shareholders convened to approve such resolution (the "Company General Meeting") (clauses (i) and (ii) collectively, the "Company Shareholder Approvals").
The Special Committee (comprising the independent directors of the Board of the Issuer) has resolved to recommend that Shareholders vote in favor of the Scheme at the Court Meeting and in favor of the Company Shareholder Resolution (the "Special Committee Recommendation").
Closing Conditions
Consummation of the Transaction is also subject to the satisfaction (or, where applicable, waiver) of certain conditions, including: (i) the Effective Date not occurring before August 23, 2026; (ii) receipt of the Company Shareholder Approvals; (iii) Court sanction of the Scheme; (iv) delivery of the Court Sanction Order (the "Court Sanction Condition"); (v) receipt of the Identified Clearances (as defined below); and (vi) absence of any injunction or other legal restraint prohibiting the Transaction. The Identified Clearances are the approval or clearance in respect of the Transaction from the following governmental authorities: (a) the Competition Commission of India; (b) the relevant Belgian federal authorities; and (c) the French Ministry of Economy and Finance.
The Reporting Person's obligation to consummate the Transaction is further conditioned on (i) accuracy of Issuer representations and warranties, subject to customary materiality qualifiers (the "Issuer Rep Bringdown Condition"); (ii) the Issuer's material compliance with covenants under the Transaction Agreement required to be performed by it at or prior to the date immediately preceding the date before the Court hearing (the "Issuer Covenant Bringdown Condition"); (iii) receipt of an officer's certificate from the Issuer confirming the foregoing clauses (i) and (ii); (iv) no continuing Company Material Adverse Effect (as defined below) as of the date before the Court Meeting; and (v) a specified third-party consent. A "Company Material Adverse Effect" means an effect that, individually or in the aggregate, either (a) results in (or would reasonably be expected to result in) (1) a reduction in the consolidated gross assets of the Issuer and its subsidiaries by more than 5% relative to gross assets to the Issuer shown in the Issuer's 2026 financial statements or (2) a reduction in the adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA") by more than 25% relative to the Adjusted EBITDA in the Issuer's 2026 financial statements or (b) would or would reasonably be expected to prevent or materially delay the ability of the Issuer to consummate the Transaction, other than to the extent resulting from any material delay in or failure to obtain any Identified Clearance, and in the case of (a), subject to customary exceptions.
The Issuer's obligation to consummate the Transaction is further conditioned on (i) accuracy of Reporting Person representations and warranties, subject to customary materiality qualifiers (the "Reporting Person Rep Bringdown Condition"); (ii) the Reporting Person's material compliance with covenants under the Transaction Agreement required to be performed by it at or prior to the date immediately preceding the date before the Court hearing (the "Reporting Person Covenant Bringdown Condition"); and (iii) receipt of an officer's certificate from the Reporting Person confirming the foregoing clauses (i) and (ii).
No Solicitation
From the date of the Transaction Agreement until the earlier of its termination in accordance with its terms and the Effective Date, the Issuer is subject to customary restrictions on its ability to, among other things, (i) solicit, initiate, participate in or knowingly facilitate any Competing Proposal (as defined below), (ii) discuss, negotiate with, or furnish non-public information to, third parties regarding a Competing Proposal, (iii) enter into any agreement relating to a Competing Proposal, or (iv) recommend or approve any Competing Proposal, withdraw, qualify amend or modify the Special Committee Recommendation in a manner adverse to the Reporting Person or fail to include the Special Committee Recommendation in the Scheme Circular (each, a "Company Adverse Recommendation Change"). A "Competing Proposal" is defined as a proposal or offer relating to the acquisition of more than 20% of the Issuer's consolidated assets or outstanding voting securities, or a merger, scheme of arrangement, business combination or similar transaction resulting in a third party holding 20% or more of such assets or securities. These restrictions are subject to customary exceptions permitting the Special Committee, subject to the other terms of the Transaction Agreement, upon receipt of a bona fide unsolicited Competing Proposal not resulting from a breach of the foregoing restrictions, (i) to furnish information to and engage in discussions with a third party in respect of a Competing Proposal if (and only if) the Special Committee determines in good faith, after consultation with its outside legal counsel and financial advisors, that the proposal constitutes, or would reasonably be expected to lead to, a Superior Proposal (as defined below) and that failing to take such action would be inconsistent with the Board's fiduciary duties, or (ii) to make a Company Adverse Recommendation Change and/or terminate the Transaction Agreement, after providing the Consortium with a customary "matching right", if the Special Committee determines in good faith, after consultation with its outside legal counsel and financial advisors, that the proposal constitutes a Superior Proposal (as defined below) and that failing to take such action would likely be inconsistent with the Board's fiduciary duties. A "Superior Proposal" is defined as a Competing Proposal meeting a more than 50% threshold of the transfer of assets or Issuer securities that the Special Committee determines in good faith, after consultation with its outside legal counsel and financial advisors, is more favorable to shareholders, including from a financial point of view, and reasonably likely to be consummated.
Termination and Fees
Either party may terminate the Transaction Agreement in certain circumstances, including if (i) the Transaction has not been consummated by the later of (a) March 31, 2027 and (b) 95 days after publication of the Scheme Circular (subject to extension); (ii) a governmental authority permanently prohibits the Transaction; (iii) the Company Shareholder Approvals are not obtained; or (iv) the Court declines to sanction the Scheme.
The Issuer may also terminate the Transaction Agreement if: (i) a Consortium member's breach causes the Reporting Person Rep Bringdown Condition or the Reporting Person Covenant Bringdown Condition, as applicable, to fail, and such breach is incurable or uncured within 60 business days (or by the Long Stop Date, if earlier); (ii) following an Intervening Event (as defined below), the Scheme is not approved at a subsequent Court meeting; or (iii) the Issuer intends to accept a Superior Proposal and concurrently enters into (or announces) a binding agreement in respect thereof, provided that the Issuer has complied with the non-solicitation and matching-rights provision.
An "Intervening Event" includes a material development affecting the Issuer that was neither known nor reasonably foreseeable to the Special Committee or the Board at signing, is unrelated to a Competing Proposal, and does not arise from the Issuer's breach or regulatory matters, subject to customary carve-outs.
The Reporting Person may terminate the Transaction Agreement if: (i) before the Court Sanction Condition is met, the Special Committee makes a Company Adverse Recommendation Change or fails to publicly reaffirm its recommendation within five business days of the Reporting Person's written request following public announcement of a Competing Proposal; (ii) an Issuer breach causes the Issuer Rep Bringdown Condition or the Issuer Covenant Bringdown Condition, as applicable, to fail, and such breach is incurable or uncured within 60 business days (or by the Long Stop Date, if earlier); or (iii) the Issuer fails to distribute the Scheme Circular as required and does not cure within 15 business days of the Reporting Person's written notice.
If the Transaction Agreement is terminated (i) by the Issuer to accept a Superior Proposal (after complying with the provisions of the Transaction Agreement described under the heading "No Solicitation"), or (ii)(a) by the Reporting Person for a Company Adverse Recommendation Change, or by either party for failure to close by the Long Stop Date or obtain Company Shareholder Approval, (b) at such time of termination, a Competing Proposal is public and not withdrawn, and (c) the Issuer enters into a definitive agreement in respect of a Competing Proposal within nine months, the Issuer must pay the Reporting Person an expense reimbursement in an amount up to $10,000,000 (including irrecoverable VAT) (the "Expense Reimbursement") concurrently with such termination, in the case of clause (i), or the entry into such definitive agreement, in the case of clause (ii). The Expense Reimbursement is the Consortium's sole and exclusive remedy against the Issuer for breach of the Transaction Agreement or the Scheme's lapse, withdrawal or non-completion, except for fraud or willful breach.
Neither party may terminate the Transaction Agreement in the event that said party's breach of any representation, warranty, covenant or obligation set out in the Transaction Agreement has caused the relevant event or circumstance giving rise to the right of termination.
Other Terms of the Transaction Agreement
Each of the Reporting Person and the Issuer made customary representations, warranties and covenants in the Transaction Agreement, including, among others, with respect to the Issuer and its subsidiaries, as applicable, covenants (i) to conduct business in the ordinary course during the period from signing to the earlier of termination of the Transaction Agreement and the consummation of the Transaction (the "Interim Period"), and (ii) not to take specified actions during the Interim Period without the Reporting Person's written consent. The Consortium has also agreed to use all reasonable endeavors to obtain the Identified Clearances, and the Issuer has agreed to cooperate with, and provide reasonably requested assistance to, the Consortium in obtaining the Identified Clearances. No member of the Consortium is obligated to accept any conditions or undertakings in order to obtain an Identified Clearance.
The foregoing description of the Transaction Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Transaction Agreement, a copy of which is filed as Exhibit 99.27 to this Schedule 13D and is incorporated herein by reference.
Transaction Announcement
On the date hereof, the Consortium and the Issuer made a joint announcement of the Transaction. A copy of the joint announcement is filed as Exhibit 99.30 to this Schedule 13D and is incorporated herein by reference. |
| (a) | See items 11 and 13 on the cover pages, which are incorporated by reference herein.
Pursuant to Section 13(d) of the Act, by virtue of the relationships described in this Schedule 13D, the Reporting Person may be deemed to be a member of a "group" with the Founder. However, the Reporting Person expressly disclaims beneficial ownership of the Shares beneficially owned by the Founder, his affiliates or any other reporting person(s). Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that the Reporting Person beneficially owns any Shares that are beneficially owned by the Founder, his affiliates or any other reporting person(s). The Reporting Person is only responsible for the information contained in this Schedule 13D and assumes no responsibility for information contained in any other Schedule 13D filed by the Founder, his affiliates or any other reporting person(s).
Pursuant to Section 13(d) of the Act, by virtue of the Irrevocable Undertakings described in this Schedule 13D, the Reporting Person may be deemed to be a member of a "group" with JERA and Platinum (each as defined below). However, the Reporting Person expressly disclaims beneficial ownership of the Shares beneficially owned by JERA and Platinum, their affiliates or any other reporting person(s). Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that the Reporting Person beneficially owns any Shares that are beneficially owned by JERA and Platinum, their affiliates or any other reporting person(s). The Reporting Person is only responsible for the information contained in this Schedule 13D and assumes no responsibility for information contained in any other Schedule 13D filed by JERA, Platinum, their affiliates or any other reporting person(s).
Based on the Schedule 13D filed by the Founder with the SEC on the date hereof, the Founder beneficially owns 60,540,417 Shares, which represent approximately 19.75% of the voting rights associated with the outstanding Shares. Based on the Schedule 13D filed by JERA with the SEC on the date hereof, JERA beneficially owns 28,524,255 Shares, which represent approximately 11.59% of the voting rights associated with the outstanding Shares. Based on the Schedule 13D filed by Platinum with the SEC on the date hereof, Platinum beneficially owns 58,170,916 Shares, which represent approximately 23.64% of the voting rights associated with the outstanding Shares.
Accordingly, in the aggregate, the Reporting Person, the Founder, JERA and Platinum may be deemed to beneficially own 236,082,432 Shares. Based on an aggregate of 318,925,017 Shares, comprised of (i) 246,038,922 Shares outstanding as of March 31, 2026, as reported by the Issuer in its Form 20-F filed with the SEC on July 30, 2026, (ii) 12,345,678 Shares that would have been issued to the Reporting Person if the Reporting Person had exchanged its existing ordinary shares in ReNew India that they hold at the relevant time for Shares at an exchange ratio of 1-to-0.8289, (iii) 11,437,723 Shares that would have been issued to the Founder and his affiliates if the Founder and his affiliates had exchanged their existing ordinary shares in ReNew India that they hold at the relevant time for Shares at an exchange ratio of 1-to-0.8289 and (iv) 49,102,694 Shares issuable to the Founder upon the exercise of options held by the Founder that were exercisable within 60 days from the date hereof, the Reporting Person, the Founder, JERA and Platinum may be deemed to beneficially own approximately 74.02% of the outstanding Shares. However, the Reporting Person expressly disclaims beneficial ownership of the Shares beneficially owned by the Founder, JERA and Platinum, their affiliates or any other reporting person(s). Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that the Reporting Person beneficially owns any Shares that are beneficially owned by the Founder, JERA and Platinum, their affiliates or any other reporting person(s). The Reporting Person is only responsible for the information contained in this Schedule 13D and assumes no responsibility for information contained in any other Schedule 13D filed by the Founder, JERA, Platinum, their affiliates or any other reporting person(s).
|
| | The information set forth in or incorporated by reference in Items 3, 4 and 5 of this Schedule 13D is incorporated by reference in its entirety into this Item 6.
Irrevocable Undertakings
In connection with the Transaction, JERA Power RN B.V. ("JERA") and Platinum Cactus A 2019 Trust ("Platinum"), holding together about 51.1% of the voting power of the Scheme Shares, each delivered an irrevocable undertaking in favor of the Consortium, pursuant to which each has agreed, among other things, to (i) vote their securities of the Issuer (the "Relevant Securities") in favor of the Scheme, the Transaction and the related resolutions (and against any resolution to adjourn the relevant shareholder meetings, amend the Scheme, or which is likely to result in a condition of the Scheme not being fulfilled, impede or frustrate the Scheme, or prevent the Scheme from becoming effective), (ii) if the Transaction is implemented by way of a takeover offer, accept that offer in respect of its Relevant Securities, (iii) elect the Rollover in respect of all their Relevant Securities; (iv) not dispose of or deal in Relevant Securities, acquire further Relevant Securities, enter third-party arrangements over Relevant Securities, or otherwise restrict control of the rights attached to their Relevant Securities, other than pursuant to the Transaction; and (v) cooperate in the implementation of the reorganization of the Issuer to be undertaken after the Effective Time and enter into the related reorganization deed and shareholders' agreement to be entered into in connection with the Transaction, and provide reasonable cooperation in connection with obtaining required regulatory clearances (subject to customary confidentiality/privilege carve-outs). Each undertaking will lapse in specified circumstances, including if the Transaction Agreement terminates, the Scheme lapses or is withdrawn, the Scheme/offer does not become effective/unconditional by the specified long-stop time, or a competing offer for all of the Issuer's share capital becomes effective or unconditional.
The foregoing description of the Irrevocable Undertakings does not purport to be complete and is qualified in its entirety by reference to the full text of the Irrevocable Undertakings, copies of which are filed as Exhibits 99.28 and 99.29 to this Schedule 13D and is incorporated herein by reference.
Form of the Shareholders' Agreement
Concurrently with the Transaction Agreement, the Consortium agreed to a form of shareholders' agreement, which is expected to be entered into at the Effective Time (the "Shareholders' Agreement") by and among the Consortium, and certain other continuing shareholders of the Issuer (and the applicable affiliates of the foregoing) that will hold the Rollover Shares (collectively, the "Investors").
The Shareholders' Agreement will govern ownership and control of the Issuer from the Effective Time until completion of the Reorganization, and RPL, the primary operating subsidiary of the Issuer, from and after the completion of the Reorganization, and will contain the following material terms (any reference to RPL below is also a reference to the Issuer for the period from and after the Effective Time until the completion of the Reorganization):
Governance
(a) Director Appointment Rights. The board of directors of the Issuer and, following completion of the Reorganization Steps, RPL will consist of the number of directors appointed in accordance with the following provisions: (i) the Investor who holds (A) an aggregate ownership interest in RPL or Issuer (as applicable) of more than 50% (on a non-diluted basis), or (B) an aggregate ownership interest of 40% or more and is the single largest ownership interest in RPL or Issuer (as applicable) (on a non-diluted basis) (in either case, the "Controlling Investor") will be entitled to appoint an unlimited number of directors; (ii) each Investor holding 10% or more of the ownership interest in RPL (on a non-diluted basis) (to the extent not already entitled to appoint an unlimited number of directors under the preceding clause) will be entitled to appoint one director; (iii) an Investor holding less than 10% of the ownership interest in RPL (on a non-diluted basis) will not hold any director appointment rights; (iv) the Founder will be entitled to serve as a director, subject to certain sunset provisions set forth in the Shareholders' Agreement and (v) any Investor holding 5% or more of the ownership interest in RPL (on a non-diluted basis) will be entitled to appoint a non-voting observer.
(b) Reserved Matters. The Shareholders' Agreement contains customary "reserved matters" provisions, which require the approval of at least 87.6% of the ownership interests in RPL (on a non-diluted basis), in some cases, and at least 95% of the ownership interests in RPL (on a non-diluted basis), in other cases, prior to RPL taking certain specified actions set forth in the Shareholders' Agreement.
Transfer Restrictions
The Shareholders' Agreement contains a three-year lock-up binding on all Investors (other than the Controlling Investor), as well as a right of first offer in favor of the Controlling Investor and tag/drag-along rights in respect of transfers by the Controlling Investor.
Indian IPO
Within 12 months following the Effective Time, the Board will establish a "Strategic Options Committee" comprised of at least five members, to include (i) the Founder (for as long as he remains a director), (ii) one member appointed by each Investor holding 12.5% or more of the ownership interests in RPL (on a non-diluted basis) and (iii) a remaining number, sufficient to comprise a majority, appointed by the Controlling Investor, to oversee preparation for the admission of RPL's ordinary shares to a recognized stock exchange.
Special Founder Rights
The Founder has certain rights under the Shareholders' Agreement, including his right to serve as chairman/vice chairman of the board of directors of the Issuer and certain liquidity rights.
The description of the form of the Shareholders' Agreement contained in this Item 4 is not intended to be complete. A more detailed description of the form of the Shareholders' Agreement will be provided in the Scheme Circular, and a copy of the form of the Shareholders' Agreement will be attached as an exhibit thereto.
Reorganization and Form of Reorganization Deed
Concurrently with the execution of the Transaction Agreement, the Consortium also agreed to the form of Reorganization Deed and the form of the steps plan attached thereto (the "Reorganization Deed"). The Reorganization Deed, which will come into effect at the Effective Time, is the legal framework agreement that will bind the Consortium and Rollover Shareholders to the legal steps (the "Reorganization Steps") that will be undertaken after the Effective Time to effect a reorganization of the Issuer and its subsidiaries (the "Reorganization"), the result of which will be that all shareholders of the Issuer at the Effective Time will become direct shareholders of RPL. The Reorganization Steps include the below steps, to occur in chronological order:
(a) Constitutional Amendments. Once consummation of the Transaction has taken place, the share capital of the Issuer, which is currently comprised of four share classes, will be harmonized into a single class of ordinary shares with pari passu voting and economic rights.
(b) The 'Re-Domicile'. Once the Issuer has been re-registered as a private company after consummation of the Transaction, it will transfer at fair market value (which, absent any significant delay between consummation of the Transaction and the re-domicile, is expected to be equivalent to the valuation considered for the purpose of the Transaction) its shares in RPL to each of the Issuer's shareholders on a pro rata basis (based on economic, rather than voting rights), which will have the effect of moving their shareholding to RPL directly. The consideration payable by each shareholder of the Issuer for the transfer of the relevant RPL shares to that shareholder will be left outstanding as a debt owed by that shareholder to the Issuer (the "Consideration Debt"). The Issuer will then immediately declare a distribution to each shareholder of an amount equal to that shareholder's Consideration Debt, and the amount owed by the Issuer to the shareholder under that distribution will be set off against the Consideration Debt so that the two amounts cancel out and no shareholder (nor the Issuer) is required to make a cash payment.
The description of the Reorganization and the form of the Reorganization Deed contained in this Item 4 is not intended to be complete. A more detailed description of the Reorganization and the Reorganization Deed will be provided in the Scheme Circular, and a copy of the Reorganization Deed will be attached as an exhibit thereto.
Founder Service Agreement
The Reporting Person and the Founder also agreed the form of a service agreement (the "Founder Service Agreement"), effective from the Effective Date, replacing the Founder's prior employment agreements with RPL and the Issuer. The Founder Service Agreement provides, among other things, that the Founder will be employed as the Chief Executive Officer of RPL, and receive a per annum basic salary of not less than INR 125,221,329 (less tax deductions required by law), inclusive of director's fees and subject to annual increase.
The Founder is also entitled to an annual bonus, subject to performance conditions, annual equity grants, and certain severance benefits.
Under the Founder Service Agreement, the Founder's existing equity awards will lapse and be replaced under a new incentive plan established by RPL. Existing awards with an exercise price per share equal to or lower than the Consideration awards will be replaced with equivalent awards subject to equivalent terms, provided, that any vested replacement awards remain exercisable until 2035. Existing options with an exercise price per share greater than the Consideration ("Founder OTM Options") will be replaced with equivalent options subject to equivalent terms, provided, that 50% will vest on the Effective Date and the remaining 50% will vest in four equal half-yearly instalments of 12.5% each, and vested replacement awards over Founder OTM Options remain exercisable until 2037. Existing RSUs or PBUs with a nominal exercise price of $0.0001 will be replaced with a number of replacement RSUs or PBUs to be determined in accordance with a calculation method prescribed in the Founder Service Agreement, subject to equivalent terms, and will remain exercisable until 2035.
The description of the form of the Founder Service Agreement contained in this Item 4 is not intended to be complete. A more detailed description of the Founder Service Agreement will be provided in the Scheme Circular, and a copy of the Founder Service Agreement will be attached as an exhibit thereto. |
